Thymidylate Synthase Expression in Hepatic Tumors Is a Predictor of Survival and Progression in Patients With Resectable Metastatic Colorectal Cancer
Authors:
- 1 February 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (3) , 406-412
Abstract
Purpose: To investigate the role of thymidylate synthase (TS),p53, and epidermal growth factor receptor (EGF-R) expressions in hepatic tumors in predicting overall survival (OS), progression-free survival (PFS), and hepatic progression-free survival (HPFS) in patients with resectable metastatic colorectal cancer who were randomly assigned to receive either systemic chemotherapy (SYS) alone or systemic and hepatic arterial infusion (HAI+SYS) chemotherapy following liver surgery. Patients and Methods: Tissues from metastatic tumors were collected during liver resection from 156 patients, and marker expressions were determined using immunohistochemistry on frozen samples. Univariate associations between marker expressions and baseline variables with OS, PFS, and HPFS were examined. Independent predictors of outcome were determined using a multivariate Cox model. Results: In multivariate analyses, TSoverexpression was found to be an independent factor of poor prognosis in OS (P < .01), PFS (P = .06), and HPFS (P < .01). In addition, resection margin was a significant independent factor for all three outcomes. Patients who received HAI+SYS experienced delayed progression in general, and in the liver, specifically. Increased levels of serum alkaline phosphatase correlated with hepatic progression. We also found a significant TS-treatment interaction for OS (P = .01) in multivariate analysis. In particular, TS+ patients receiving HAI+SYS had significantly higher survival than those receiving SYS (64 monthsv 21 months; P = .01). Conclusion: TSlevels in hepatic tumors and resection margin are independent predictors of survival and progression in patients with metastatic colorectal cancer, whereasp53and EGFRare not independent predictors. Treatment with HAI+SYS significantly improved the survival profile of TS+ patients.Keywords
This publication has 25 references indexed in Scilit:
- Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon CancerJournal of Clinical Oncology, 2002
- Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapyCancer, 2000
- Hepatic Arterial Infusion of Chemotherapy after Resection of Hepatic Metastases from Colorectal CancerNew England Journal of Medicine, 1999
- Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system11No competing interests declared.Journal of the American College of Surgeons, 1999
- Hepatic resection for colorectal metastasesDiseases of the Colon & Rectum, 1999
- Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastasesJournal of Surgical Oncology, 1998
- Clinical relevance of transforming growth factor α, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumorsHepatology, 1998
- Determinants of Survival following Hepatic Resection for Metastatic Colorectal CancerWorld Journal of Surgery, 1998
- Surgical Margin in Hepatic Resection for Colorectal MetastasisAnnals of Surgery, 1998
- One hundred patients with hepatic metastases from colorectal cancer treated by resection: Analysis of prognostic determinantsBritish Journal of Surgery, 1991